Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.

Abstract

A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis.

• Authors: A Fornasiero, O Daniele, V P Fosser, A Paccagnella, L Salvagno, V C Sileni, P Morandi, M V Fiorentino
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 70 Issue 5 Pg. 647-9 (May 1986) ISSN: 0361-5960 [Print] United States
• PMID: 3708613 (Publication Type: Journal Article)

Chemical References

• Heparin
• Peptichemio
• Melphalan

Topics

• Breast Neoplasms (drug therapy, pathology)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Hematologic Diseases (chemically induced)
• Heparin (therapeutic use)
• Humans
• Melphalan (analogs & derivatives)
• Middle Aged
• Neoplasm Metastasis
• Peptichemio (administration & dosage, adverse effects, therapeutic use)
• Thrombophlebitis (prevention & control)